The Latest Cardiac and Vascular News
MORRISVILLE, N.C., March 22, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 2,000 shares of Liquidia’s common stock to a newly hired non-executive employee under the […]
– Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder – Expanded use of Treprostinil Injection to include subcutaneous administration – Preparing to launch YUTREPIA in late-2022 pending final FDA approval – Company to host webcast and conference call today at 8:30 a.m. ET […]
MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the […]
MORRISVILLE, N.C., Jan. 03, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds […]
– Increased adoption of generic Treprostinil Injection by patients, physicians and payers – Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities – Anticipate FDA action on LIQ861 near PDUFA goal date of November 7, 2021 MORRISVILLE, N.C., […]
No Form 483 observations were issued during 5-day inspection MORRISVILLE, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection (PAI) of its […]
Launched subcutaneous delivery of Treprostinil Injection, doubling market opportunity Resubmitted New Drug Application (NDA) for LIQ861 (treprostinil) inhalation powder Improved balance sheet with private placement and increased financial discipline Company to host webcast and conference call today at 8:30 a.m. ET […]
MORRISVILLE, N.C., June 02, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for LIQ861 (treprostinil) inhalation powder to treat pulmonary arterial hypertension […]
Sandoz Generic Treprostinil Injection now available for both routes of administration, subcutaneous and intravenous MORRISVILLE, N.C., May 24, 2021 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) (“Liquidia” or the “Company”) today announced that Sandoz Treprostinil Injection, a generic form of […]
– Doubled the market opportunity for Treprostinil Injection by adding subcutaneous delivery – Resubmitted New Drug Application for LIQ861 (treprostinil) Inhalation Powder – Improved financial position with private placement and access to new credit facility – Company to host webcast […]
